Report: Cynthia E. Keen
However, the screening process, which includes prostate-specific antigen (PSA) testing followed by transrectal ultrasound-guided biopsy of men with elevated PSA levels of 3 ngml and higher, is responsible for overdiagnosis and excessive biopsies of low-grade prostate cancer. In fact, the World Health Organisation (WHO) Region Europe does not recommend systematic screening, citing a “high harm/benefit ratio”.
Stockholm3 test (A3P Biomedical AB, Stockholm) -- reduced the number of MRIs performed by 36%, while further preventing the need to biopsy minor, low-risk tumours by 8%. ‘Our results show that we have identified the tools needed to carry out effective and safe screening for prostate cancer,’ said Tobias Nordström MD PhD, principal investigator of the STHLM3MRI study. ‘After many years of debate and research, it feels fantastic to be able to present knowledge that can improve healthcare for men.’
Prostate cancer is the third highest cause of cancer deaths in the European Union, with an estimated 78,800 men dying in 2020. Globally, it is the sixth leading cause of cancer death among men, with an estimated 359,000 deaths in 2018 based on the GLOBOCAN database, and is estimated to increase to 740,000 deaths by 2040 due to an aging population.
Contact Person: Mrs. Helen Bo
Tel: 86-13382885910
Fax: 86-510-85572789
